EP0633781A4 - Compositions and methods for treating benign prostatic hypertrophy. - Google Patents

Compositions and methods for treating benign prostatic hypertrophy.

Info

Publication number
EP0633781A4
EP0633781A4 EP93908738A EP93908738A EP0633781A4 EP 0633781 A4 EP0633781 A4 EP 0633781A4 EP 93908738 A EP93908738 A EP 93908738A EP 93908738 A EP93908738 A EP 93908738A EP 0633781 A4 EP0633781 A4 EP 0633781A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
benign prostatic
prostatic hypertrophy
treating benign
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93908738A
Other languages
German (de)
French (fr)
Other versions
EP0633781A1 (en
Inventor
Jacob Paul Hieble
Brian Walter Metcalf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0633781A1 publication Critical patent/EP0633781A1/en
Publication of EP0633781A4 publication Critical patent/EP0633781A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
EP93908738A 1992-04-02 1993-04-02 Compositions and methods for treating benign prostatic hypertrophy. Withdrawn EP0633781A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86211792A 1992-04-02 1992-04-02
US862117 1992-04-02
US99779292A 1992-12-29 1992-12-29
US997792 1992-12-29
PCT/US1993/003145 WO1993019758A1 (en) 1992-04-02 1993-04-02 Compositions and methods for treating benign prostatic hypertrophy

Publications (2)

Publication Number Publication Date
EP0633781A1 EP0633781A1 (en) 1995-01-18
EP0633781A4 true EP0633781A4 (en) 1995-04-19

Family

ID=27127672

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93908738A Withdrawn EP0633781A4 (en) 1992-04-02 1993-04-02 Compositions and methods for treating benign prostatic hypertrophy.

Country Status (8)

Country Link
EP (1) EP0633781A4 (en)
JP (1) JPH07505398A (en)
KR (1) KR950700746A (en)
AU (1) AU668157B2 (en)
CA (1) CA2133440A1 (en)
MX (1) MX9301939A (en)
NZ (1) NZ251658A (en)
WO (1) WO1993019758A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical compositions for treatment of benign prostatic hyperplasia comprising a steroid derivative
AU7719894A (en) * 1993-09-03 1995-03-22 Smithkline Beecham Corporation Stabilized tablet formulation
AU688498B2 (en) * 1994-04-14 1998-03-12 Merck & Co., Inc. Alpha1c adrenergic receptor antagonists
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016213A1 (en) * 1991-03-20 1992-10-01 Merck & Co., Inc. Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
US4963547A (en) * 1988-06-01 1990-10-16 Smithkline Beecham Corporation Alpha-andrenergic receptor antagonists and use thereas
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016213A1 (en) * 1991-03-20 1992-10-01 Merck & Co., Inc. Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9319758A1 *

Also Published As

Publication number Publication date
AU668157B2 (en) 1996-04-26
KR950700746A (en) 1995-02-20
MX9301939A (en) 1994-08-31
EP0633781A1 (en) 1995-01-18
NZ251658A (en) 1996-08-27
WO1993019758A1 (en) 1993-10-14
CA2133440A1 (en) 1993-10-14
JPH07505398A (en) 1995-06-15
AU3945193A (en) 1993-11-08

Similar Documents

Publication Publication Date Title
EP0611302A4 (en) Methods and compositions for treating allergic reactions.
AU6393896A (en) Method for treating benign prostatic hyperplasia with thermal therapy
HUP0001454A3 (en) Compositions and methods for treating plants with exogenous chemicals
EP0650844A3 (en) Shuttle-type-printers and methods for operating same.
EP0650370A4 (en) Methods and compositions for targeting specific tissue.
ZA97860B (en) Skin smoothing compositions containing hydroxyacids and methods for using same.
EP1014995A4 (en) Compositions and methods for preventing restenosis following revascularization procedures
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
ZA971964B (en) Azolobenzazepine derivatives and compositions and method of use thereof.
PL332085A1 (en) Agents for treating prostata gland hypertrophy and carcinoma
EP0640097A4 (en) Compositions and methods for vaccination against coronaviruses.
ZA981600B (en) Methods and compositions for treating stickies
EP0855910A4 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
EP0462668A3 (en) New 17beta-aminobenzoyl-4-aza-5alpha-androst-1-en-3-ones as benign prostatic hypertrophy agents
HU9501286D0 (en) Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
EP0633781A4 (en) Compositions and methods for treating benign prostatic hypertrophy.
GB2309990B (en) Compositions and processes for treating hydrocarbon-bearing formations
AU5594398A (en) Methods and compositions for preventing and treating bone loss
IL137954A0 (en) Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia
AU5791698A (en) Methods and compositions for preventing and treating bone loss
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
AU5457694A (en) Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
EP0737204A4 (en) Cs-1 peptidomimetics, compositions and methods of using the same
IL122316A0 (en) Melatonin agonists for treating benign prostatic hyperplasia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941011

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950302

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980326

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980806

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1012275

Country of ref document: HK